## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/441,055	11/16/1999	YOSHIHIRO USUDA	0010-1057-0 3806	
22850 7590 06/14/2007 OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.		EXAMINER		
1940 DUKE STREET			FRONDA, CHRISTIAN L	
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER
			1652	
			NOTIFICATION DATE	DELIVERY MODE
			06/14/2007	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

	Application No.	Applicant(s)				
Official Actions Commence	09/441,055	USUDA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Christian L. Fronda	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 19 Ma	arch 2007					
<u> </u>	·					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
<i>,</i> —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-9.11-31 and 35 is/are pending in the	☑ Claim(s) <u>1-9,11-31 and 35</u> is/are pending in the application.					
•	4a) Of the above claim(s) <u>1-9 and 11-30</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	_					
6)⊠ Claim(s) <u>31 and 35</u> is/are rejected.	<u> </u>					
7) Claim(s) is/are objected to.	•					
8) Claim(s) are subject to restriction and/or	election requirement					
Application Papers						
<u> </u>						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)⊠ All b)□ Some * c)□ None of:						
<ol> <li>Certified copies of the priority documents</li> </ol>	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date  5) Notice of Informal Patent Application					
B) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application 6) Other:						

Art Unit: 1652

### **DETAILED ACTION**

- 1. Claims 1-9, 11-30, 31, and 35 are pending and under consideration in this Office Action. Claims 1-9 and 11-30 have been previously withdrawn from consideration.
- 2. Claims 31 and 35 are under consideration in this Office Action.
- 3. The rejection of claims 31 and 35 under 35 U.S.C. 103(a) has been withdrawn in view of the significant amendment to the claims filed in the amendment dated 03/19/2007. New rejection and new ground of rejection are presented below.

### Claim Rejections - 35 U.S.C. § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 31 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Michaeli et al. (Advances in Polyamine Research (1983), 4, 519-20; reference of record PTO 892) in view of the combined teachings or Greene (Escherichia coli and Salmonella Cellular and Molecular Biology, 2nd Edition, pps. 542-560, "BIOSYNTHESIS OF METHIONINE", 1996; PTO 1449 of IDS dated 02/16/2000) and Park et al. (Bioorg Med Chem. 1996 Dec;4(12):2179-85).

Michaeli et al. teach a process for producing L-methionine comprising culturing recombinant strains of E.coli having multicopy plasmids containing the metA gene which codes for homoserine transsuccinylase, the first enzyme in the methionine biosynthesis pathway (see entire publication).

The claims differ from the teachings of Michaeli et al. in that Michaeli et al. does not teach the a recombinant *Escherichia* bacterium deficient in the metJ gene encoding a repressor of the L-methionine biosynthesis system.

Art Unit: 1652

Greene teaches the *E.coli* repressor of the L-methionine biosynthesis system encoded by the metJ gene (see entire publication, especially p. 552).

Park et al. teach the enzyme *E.coli metk* gene encoding S-adenosylmethionine synthetase which catalyzes the synthesis of S-adenosyl-L-methionine (SAM), where SAM is a major methyl group transfer agent in biological systems and the methyl moiety of SAM is transferred to proteins, lipids, nucleic acids, and vitamins by SAM-dependent methyltransferases (see abstract and entire publication).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the process of Michaeli et al. such that the metJ gene taught by Greene is inactivated in order to make the recombinant *E.coli* having multicopy plasmids containing the metA gene taught by Michaeli et al. deficient in the *E.coli* repressor of the L-methionine biosynthesis system and reduce activity of the intracellular S-adenosylmethionine synthetase taught by Park et al. One of ordinary skill in the art at the time the invention was made would have been motivated to do this for the purposes of having a simple culturing method that produces L-methionine, where inactivation of the metJ gene encoding the *E.coli* repressor of the L-methionine biosynthesis system would lead to increased amounts of produced L-methionine and reduced intracellular S-adenosylmethionine synthetase leads to reduced transfer of methyl moieties for the production of SAM by action of S-adenosylmethionine synthetase. One of ordinary skill in the art at the time the invention was made would have had a reasonable expectation of success since recombinant molecular biology techniques for inactivating genes are well known and developed in the art.

#### Conclusion

- 6. No claim is allowed.
- 7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1652

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.
- 9. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**CLF** 

TEKCHAND SAIDHA PRIMARY EXAMINER